<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134673">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143479</url>
  </required_header>
  <id_info>
    <org_study_id>FR-Adv-NI-002</org_study_id>
    <nct_id>NCT02143479</nct_id>
  </id_info>
  <brief_title>A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year</brief_title>
  <acronym>COBALT</acronym>
  <official_title>A Cohort Study in Liver Transplant Patients Converted From a Tacrolimus Twice a Day (Prograf®) to Tacrolimus Once a Day (Advagraf®). French, Multisite, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in which two groups of patients will be analysed; patients converted from Prograf to
      Advagraf within the first 3 months after transplantation and patients converted from Prograf
      to Advagraf between 3 months and 1 year after transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Conversion ratio of the daily dose of tacrolimus (mg Prograf® / mg Advagraf®)</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with a conversion ratio of tacrolimus dose of 1mg/1mg and percentage of patients with a ratio differing from 1mg/1mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the first tacrolimus trough level (C0) after conversion</measure>
    <time_frame>From baseline to first determination of C0 (up to 6 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days between the conversion date and the date of the first determination of C0 after conversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of additional visits considered by the physicians to be due to the conversion (if required)</measure>
    <time_frame>At 6 months and at 1 year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with additional visit(s) and percentage of patients without an additional visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reasons for conversion</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of pills, number of treatment intake, treatment compliance, physician request, patient request, safety of treatment, center practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient profile</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sociodemographic data, history of transplantation, comorbidities, complications after transplantation, risk factors, concomitant treatments (other than immunosuppressive protocols) and modification, if required, at 6 months and 1 year after conversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of immunosuppressive protocol details</measure>
    <time_frame>At baseline, 6 months and 1 year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Date of initiation of treatment with Advagraf®
Target tacrolimus C0 (with Prograf® and with Advagraf® and recommendations for administration)
Daily dose of Advagraf®
Adjustments to Advagraf® dose since the previous visit: date, doses and reason for adjustment
Type and dose of immunosuppressive drugs combined with Advagraf®
Modification of the immunosuppressive regimen at 6 months and 1 year after conversion (if applicable) since the previous visit: date, modified treatment, type of modification, reason for modification
Immunosuppressive regimen at the end of the visit at 6 months and 1 year after conversion, modified treatment, type of modification, reason for modification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach steady state</measure>
    <time_frame>From baseline to first determination of C0 (up to 6 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose ratio at steady state</measure>
    <time_frame>From baseline and up to 6 months post-conversion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ratio of daily dose of tacrolimus during achievement of steady state: mg Prograf® at conversion/mg Advagraf® during achievement of steady state. Percentage of patients with a ratio of 1mg/1mg and percentage of patients with a ratio differing from 1mg/1mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Intra -Patient Variability (IPV) of tacrolimus in patients on Prograf® and Advagraf ®</measure>
    <time_frame>At baseline (Prograf) and during the 45 days after conversion (Advagraf)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latest available laboratory data with Prograf® before conversion and with Advagraf®</measure>
    <time_frame>At baseline, 6 months and 1 year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Values and dates for renal parameters, liver parameters, blood glucose and Hepatitis C viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with treatment at conversion</measure>
    <time_frame>At  baseline and at 1 year after conversion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compliance with treatment at conversion (with Prograf® and only in group 2) and at 1 year after conversion (with Advagraf® for both groups) will be assessed using the Morisky questionnaire and a score will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life at conversion</measure>
    <time_frame>At  baseline and at 1 year after conversion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients' quality of life at conversion (with Prograf® only in group 2) and at 1 year after conversion (with Advagraf® for both groups) will be assessed using the European Quality of Life-5 Dimensions 5 level (EQ5D-5L) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute rejection proven by biopsy (BPAR), graft survival rate and patient survival rate</measure>
    <time_frame>6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be assessed on the basis of the number of acute rejections confirmed by biopsy and recorded adverse events and adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events and/or effects</measure>
    <time_frame>From baseline until 1 year follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>1:early conversion from Prograf® to Advagraf®</arm_group_label>
    <description>patients converted from Prograf® to Advagraf® in the first 3 months after transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:late conversion from Prograf® to Advagraf®</arm_group_label>
    <description>patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>oral</description>
    <arm_group_label>1:early conversion from Prograf® to Advagraf®</arm_group_label>
    <arm_group_label>2:late conversion from Prograf® to Advagraf®</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf</intervention_name>
    <description>oral</description>
    <arm_group_label>1:early conversion from Prograf® to Advagraf®</arm_group_label>
    <arm_group_label>2:late conversion from Prograf® to Advagraf®</arm_group_label>
    <other_name>FK506E</other_name>
    <other_name>tacrolimus</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Liver transplant patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a liver transplant performed in the previous year and for whom the
             conversion from Prograf® to Advagraf® was decided by the physician.

        Exclusion Criteria:

          -  Patient participating in an interventional clinical trial at the time of enrolment
             into the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical and Scientific Affairs Manager, Transplantation</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma S.A.S.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Dept Clinical Operations Dept</last_name>
    <phone>+ 31 (0)71 5455050</phone>
    <email>contact@nl.astellas.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmaco-epidemiology</keyword>
  <keyword>Prograf</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>France</keyword>
  <keyword>Observational</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
